EGCG suppresses PD-1 expression of T cells via inhibiting NF- κB phosphorylation and nuclear translocation

Int Immunopharmacol. 2024 Apr 20;133:112069. doi: 10.1016/j.intimp.2024.112069. Online ahead of print.ABSTRACTEpigallocatechin-3-gallate (EGCG) is an important tea polyphenol with anti-tumor potential. Our previous studies revealed that EGCG was a promising immune checkpoint inhibitor (ICI) as it could downregulate expression of programmed cell death 1 ligand 1 (PD-L1) in tumor cells, thereby resulting tumor killing effect. In particular, EGCG can effectively avoid the inflammatory storm caused by anti-tumor therapy, which is a healthy green capacity absent from many ICIs. However, the relationship between EGCG and programmed cell death 1 (PD-1) of T cells remains unclear. In this work, we explored the effect of EGCG on T cells and found that EGCG suppressed PD-1 via inhibiting NF-κB phosphorylation and nuclear translocation. Furtherly, the capability of EGCG was confirmed in tumor-bearing mice to inhibit PD-1 expression in T cells and enhance apoptosis in tumor cells. These results implied that EGCG could inhibit the expression of PD-1 in T cells, thereby promoting anti-tumor effects of T cells. EGCG will be a promising candidate in anti-tumor therapy.PMID:38643710 | DOI:10.1016/j.intimp.2024.112069

Source: International Immunopharmacology - April 21, 2024 Category: Allergy & Immunology Authors: Zhong-Da Li Fangfang Liu Yanqiao Zeng Yingnan Liu Wenhe Luo Feng Yuan Su Li Qi Li Jiaxin Chen Mayumi Fujita Guofang Zhang Yang Li Source Type: research